Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 1, 2011, Pages 193-200

  O'Reilly, Terence ^a   Lane, Heidi A ^a   Wood, Jeanette M ^a   Schnell, Christian ^a   Littlewood Evans, Amanda ^a   Brueggen, Josef ^a   McSheehy, Paul M J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiogenesis; Anti tumour activity; Everolimus; mTOR; PK PD; PTK ZK; VEGF R TKI

Indexed keywords

EVEROLIMUS; VASCULOTROPIN; VATALANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CERVICAL LYMPH NODE; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; IN VIVO STUDY; LYMPH NODE METASTASIS; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PHTHALAZINES; PROTEINS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS;

EID: 78651105834     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1307-z     Document Type: Article

References (22)

1. A Boulay HA Lane 2007 The mammalian target of rapamycin kinase and tumor growth inhibition Recent Results Cancer Res 172 99 124 1:CAS:528: DC%2BD2sXpsleitr0%3D 10.1007/978-3-540-31209-3-7 17607938
2. S Mabuchi DA Altomare M Cheung L Zhang PI Poulikakos HH Hensley RJ Schilder RF Ozols JR Testa 2007 RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model Clin Cancer Res 13 4261 4270 1:CAS:528: DC%2BD2sXnvVChtr4%3D 10.1158/1078-0432.CCR-06-2770 17634556 (Pubitemid 47105991)
3. S Mabuchi DA Altomare DC Connolly A Klein-Szanto S Litwin MK Hoelzle HH Hensley TC Hamilton JR Testa 2007 RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer Cancer Res 67 2408 2413 1:CAS:528:DC%2BD2sXivV2guro%3D 10.1158/0008-5472.CAN-06-4490 17363557 (Pubitemid 46548923)
4. PC Manegold C Paringer U Kulka K Krimmel ME Eichhorn R Wilkowski KW Jauch M Guba CJ Bruns 2008 Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer Clin Cancer Res 14 892 900 1:CAS:528:DC%2BD1cXhsFyktLg%3D 10.1158/1078-0432.CCR-07- 0955 18245553 (Pubitemid 351231174)
5. HA Lane JM Wood PM McSheehy PR Allegrini A Boulay J Brueggen A Littlewood-Evans SM Maira G Martiny-Baron CR Schnell P Sini T O'Reilly 2009 mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor Clin Cancer Res 15 1612 1622 1:CAS:528:DC%2BD1MXisVWrsr0%3D 10.1158/1078-0432.CCR-08-2057 19223496
6. JM Wood G Bold E Buchdunger R Cozens S Ferrari J Frei F Hofmann J Mestan H Mett T O'Reilly E Persohn J Rösel C Schnell D Stover A Theuer H Towbin F Wenger K Woods-Cook A Menrad G Siemeister M Schirner KH Thierauch MR Schneider J Drevs G Martiny-Baron F Totzke 2000 PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60 2178 2189 1:CAS:528:DC%2BD3cXivVaksb0%3D 10786682
7. M Rudin PM McSheehy PR Allegrini M Rausch D Baumann M Becquet K Brecht J Brueggen S Ferretti F Schaeffer C Schnell J Wood 2005 PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo NMR Biomed 18 308 321 1:CAS:528:DC%2BD2MXhtVenu7%2FF 10.1002/nbm.961 15918178 (Pubitemid 41158696)
8. S Ferretti PR Allegrini T O'Reilly C Schnell M Stumm M Wartmann J Wood PM McSheehy 2005 Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure Clin Cancer Res 11 7773 7784 1:CAS:528:DC%2BD2MXhtF2isL7K 10.1158/1078-0432.CCR- 05-1165 16278399 (Pubitemid 41611621)
9. P Sini I Samarzija F Baffert A Littlewood-Evans C Schnell A Theuer S Christian A Boos H Hess-Stumpp JA Foekens B Setyono-Han J Wood NE Hynes 2008 Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics Cancer Res 68 1581 1592 1:CAS:528:DC%2BD1cXislansrg%3D 10.1158/0008-5472.CAN-06-4685 18316624 (Pubitemid 351346868)
10. K LaMontagne A Littlewood-Evans C Schnell T O'Reilly L Wyder T Sanchez B Probst J Butler A Wood G Liau E Billy A Theuer T Hla J Wood 2006 Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization Cancer Res 66 221 231 1:CAS:528:DC%2BD28XhsFWgsg%3D%3D 10.1158/0008-5472.CAN-05-2001 16397235 (Pubitemid 43166028)
11. R Hirayama K Sato K Hirokawa MP Chang Y Mishima T Makinodan 1984 Different metastatic modes of malignant melanoma implanted in the ear of young and old mice Cancer Immunol Immunother 18 209 214 1:STN:280: DyaL2M%2FnsVWktA%3D%3D 10.1007/BF00205513 6568876
12. T O'Reilly PMJ McSheehy R Kawai O Kretz L McMahon J Bryeggen A Bruelisauer HP Gschwind PR Allegrini HA Lane 2010 Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents Cancer Chemother Pharmacol 65 625 639 10.1007/s00280-009-1068-8 19784839
13. R Clarke 1997 Issues in experimental design and endpoint analyses in the study of experimental cytotoxic agents in vivo in breast cancer and other models Breast Cancer Res Treat 46 255 287 1:CAS:528:DyaK1cXhtFWmtLo%3D 10.1023/A:1005938428456 9478280 (Pubitemid 28029528)
14. Taylor JK (1990) Statistical techniques for data analysis. Lewis Publishers, Boca Raton, pp 81-83
15. S Ferretti PR Allegrini MM Becquet PM McSheehy 2009 Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics Neoplasia 11 874 881 1:CAS:528:DC%2BD1MXhtVKht7jM 19724681
16. B Kuhn W Jacobsen U Christians LZ Benet PA Kollman 2001 Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations J Med Chem 44 2027 2034 1:CAS:528:DC%2BD3MXjtlCksbY%3D 10.1021/jm010079y 11384247 (Pubitemid 32884525)
17. M Paez-Ribes E Allen J Hudock 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 220 231 1:CAS:528:DC%2BD1MXltFSmtbY%3D 10.1016/j.ccr.2009.01.027 19249680
18. A Alphonso SK Alahari 2009 Stromal cells and integrins: conforming to the needs of the tumor microenvironment Neoplasia 11 1264 1271 1:CAS:528: DC%2BD1MXhsFejurnI 20019834
19. A Eberhard S Kahlert V Goede B Hemerlein KH Plate HG Augustin 2000 Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies Cancer Res 60 1388 1393 1:CAS:528:DC%2BD3cXhvFWrtL0%3D 10728704
20. Y Yonenaga A Mori H Onodera S Yasuda H Oe A Fujimoto T Tachibana M Imamaura 2005 Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients Oncology 69 159 166 10.1159/000087840 16127287 (Pubitemid 41376915)
21. Speca JC, Mears AL, Creel PA, Yenser SE, Bendell JC, Morse MA, Hurwitz HI, Armstrong AJ, George DJ (2007) Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. J Clin Oncol 25(18-suppl) ASCO Meeting Abstract: 5039
22. Dy GK, Croghan GA, Qi Y, Glockner J, Hanson L, Roos M, Tan AD, Molina JR, Adjei AA (2008) Phase I trial of the mTOR inhibitor RAD001 (R) in combination with two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 (P) in patients (pts) with advanced solid tumors. J Clin Oncol 26 (15-suppl) ASCO Meeting Abstract: 2529